Skip to main content

Prostate Cancer

Exploratory Real-World Comparative Analysis of Abiraterone Dosing Strategies
Ellen M. Hulterstrum, PharmD, BCOP; Carlina J. Grindeland, PharmD, BCPS, BCPPS; Megan Czmowski, PharmD, BCOP
Read More
Online First
Exemestane Treatment in a Male Patient With Concurrent Breast and Prostate Cancers: A Case Report
Bryan P. Fitzgerald, PharmD; Allison Magnuson, DO, MS; Chunkit Fung, MD
Read More
Comparing the Impact of Abiraterone and Enzalutamide Sequencing on Progression-Free Survival in Veterans with Metastatic Castration-Resistant Prostate Cancer
Nicholas J. Newman, PharmD; Sara E. Gordon, PharmD, BCOP; Charles J. Nock, MD; Christopher J. Burant, PhD; Candice M. Wenzell, PharmD, BCOP
Read More
Meeting Highlights Online Only
Genetic Score Makes PSA Screening More Accurate
Read More
Comparison of Second-Generation Antiandrogens for the Treatment of Prostate Cancer
Seon Jo Park, PharmD, BCOP; Benjamin Yoder, PharmD; Tammy Li, PharmD
Read More
Pluvicto FDA Approved for PSMA-Positive Metastatic Prostate Cancer
Read More
Darolutamide plus ADT and Docetaxel Improves Survival in Men with Metastatic Hormone-Sensitive Prostate Cancer
Read More
Continuous Treatment with Enzalutamide and Docetaxel Reduces the Risk for Progression in Patients with Metastatic Castration-Resistant Prostate Cancer
Read More
Meeting Highlights
¹⁷⁷Lu-PSMA-617 Prolongs Survival in Patients with Metastatic Castration-Resistant Prostate Cancer
Phoebe Starr
Read More
Orgovyx First FDA-Approved Oral Hormone Therapy for Advanced Prostate Cancer
Read More
Page 1 of 2
Results 1 - 10 of 15